Ironwood Pharmaceuticals (IRWD) Total Non-Current Liabilities (2011 - 2026)

Ironwood Pharmaceuticals has disclosed Total Non-Current Liabilities across 15 years of filings, most recently posting $426.4 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities fell 32.17% year-over-year to $426.4 million; the TTM figure through Jun 2026 stood at $426.4 million (down 32.17% YoY), while the FY2025 annual figure was $637.1 million, changed 0.31% from the prior year.
• Total Non-Current Liabilities came in at $426.4 million for Q2 2026 at Ironwood Pharmaceuticals, down from $630.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $919.0 million in Q2 2023 to a low of $426.4 million in Q2 2026.
• Average Total Non-Current Liabilities over 5 years is $620.1 million, with a median of $636.1 million recorded in 2024.
• Year-over-year, Total Non-Current Liabilities soared 110.62% in 2023 and plunged 32.17% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $438.4 million in 2022, then surged by 79.97% to $789.0 million in 2023, then decreased by 19.5% to $635.1 million in 2024, then climbed by 0.31% to $637.1 million in 2025, then sank by 33.06% to $426.4 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $426.4 million in Q2 2026, $630.5 million in Q1 2026, and $637.1 million in Q4 2025.